Morning Trend | SINO BIOPHARM rebounds from low points, will a rebound window open?

SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking and market participants showing strong wait-and-see sentiment. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, indicating a large divergence between bulls and bears in the short term. Fundamentally, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it is affected by industry medical insurance cost control, centralized procurement pressures, and a slowdown in sequential performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading enthusiasm. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic headwinds that have further suppressed risk appetite for capital. Technically, current support is located in the HKD 3.5-3.8 range, which has historically seen rebounds after multiple touches. However, the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. Conversely, if the price breaks support on low volume, there may be a risk of inertia downward movement. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes alongside unusual movements in incremental funds, light participation in short-term opportunities may be considered, with an overall focus on stability and risk control as a priority